LEO Pharma to Acquire Timber Pharmaceuticals

[cafead]

via LEO Pharma announced today its acquisition of Timber Pharmaceuticals, a transaction valued at $36 million.1 Timber Pharmaceuticals has been evaluating the safety and efficacy of its breakthrough therapy, TMB-001, for the treatment of congenital ichthyosis (CI). TMB-001, a topical isotretinoin formulation, was granted Fast Track Designation in April 2022 and Breakthrough Therapy Designation in May 2022 by the FDA. With no other FDA-approved treatments available for patients with CI, Timber Pharmaceuticals has been working tirelessly toward approval.

article source